A Phase II Study of BAY 43-9006 [sorafenib] in Combination With Bicalutamide in Patients With Chemo-Naive Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2010
At a glance
- Drugs Sorafenib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 04 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.